Cover

Guides Introduction to combination therapy

Other nukes

AZT and Combivir

AZT is a twice-daily nuke that has been widely prescribed and studied, but is now used less often in first-line treatment.

It used to be widely used during pregnancy. However. this is now thought less important as there are other drugs.

Combivir is a fixed-dose combination of AZT and 3TC that is taken twice-daily.

The disadvantages of AZT are the side effects of anaemia, fatigue and lipoatrophy (fat loss). Lipoatrophy does not usually occur during the first six months of AZT treatment.

ddI

ddI is rarely used as a first-line choice, because is less effective and less convenient. It needs to be taken on an empty stomach (ie two hours after food). ddI is mainly used in people with drug resistance.

Triple nuke combinations

Triple-nuke combinations are not recommended as first-line treatment as they are less effective.

The main reason to use a triple-nuke combination is to reduce side effects related to PIs or NNRTIs or if there are interactions between these drugs and other medications (ie for TB).

Nukes that don’t mix

Although one nuke can often be switched for another.

The table below shows some combinations that should never be used.

AZT and d4T At any time
FTC and 3TC At any time
ddI and tenofovir Especially with an NNRTI
abacavir and tenofovir In a 3 drug combo until an interaction is explained
d4T and ddI Never during pregnancy
Triple-nuke combinations Only two combinations – AZT + 3TC + abacavir or AZT + 3TC + tenofovir – can be used. Others have a high risk of failure

July 2010

Decisions relating to your treatment should always be taken in consultation with your doctor. Information in this guide is intended to support those discussions.

Authors and referencesTranslationsAbout our guidesGuides index

This guide's available in UK clinics (can't find it?)

We comply with the HONcode standard for trustworthy health information: verify here



HIV i-Base
Treatment phoneline: 0808 800 6013 • Mon-Wed 12-4pm • Office: 020 7407 8488 • Email: admin@i-base.org.uk • Website: www.i-base.info